Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2

Top Cited Papers
Open Access
Abstract
The randomized, double-blind, Breast Cancer Prevention Trial (BCPT) was conducted between 1992 and 1998 by the National Surgical Adjuvant Breast and Bowel Project (NSABP). The purpose of the BCPT was to determine whether tamoxifen use by cancer-free, high-risk women significantly altered incidence of invasive breast cancer.1 The result of the BCPT, which involved 13 388 women, was that the incidence of invasive breast cancer among those randomized to tamoxifen compared with those randomized to placebo (risk ratio [RR]) was 0.51.